Literature DB >> 29371640

Clinical utility gene card for McArdle disease.

Rhonda L Taylor1,2, Mark Davis3, Emma Turner1,2, Astrid Brull4, Tomás Pinos5,6, Macarena Cabrera7, Kristen J Nowak8,9,10.   

Abstract

Name of the disease (synonyms) McArdle disease (glycogenosis type V; glycogen storage disease V (GSDV); PYGM deficiency; muscle glycogen phosphorylase deficiency; myophosphorylase deficiency). OMIM# of the disease #232600. Name of the analysed genes or DNA/chromosome segments Muscle glycogen phosphoryalse (PYGM). OMIM# of the gene(s) #608455.Review of the analytical and clinical validity as well as of the clinical utility of DNA-based testing for variants in the PYGM gene(s) in⊠ diagnostic,⊠ predictive and⊠ prenatal settings and for⊠ risk assessment in relatives.

Entities:  

Mesh:

Year:  2018        PMID: 29371640      PMCID: PMC5945672          DOI: 10.1038/s41431-017-0070-6

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  23 in total

Review 1.  Percutaneous needle biopsy of skeletal muscle in physiological and clinical research.

Authors:  J Bergstrom
Journal:  Scand J Clin Lab Invest       Date:  1975-11       Impact factor: 1.713

2.  The effect of oral sucrose on exercise tolerance in patients with McArdle's disease.

Authors:  John Vissing; Ronald G Haller
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

3.  A diagnostic cycle test for McArdle's disease.

Authors:  John Vissing; Ronald G Haller
Journal:  Ann Neurol       Date:  2003-10       Impact factor: 10.422

4.  Adenovirus and adeno-associated virus-mediated delivery of human myophosphorylase cDNA and LacZ cDNA to muscle in the ovine model of McArdle's disease: expression and re-expression of glycogen phosphorylase.

Authors:  J McC Howell; K R Walker; L Davies; E Dunton; A Everaardt; N Laing; G Karpati
Journal:  Neuromuscul Disord       Date:  2008-03-14       Impact factor: 4.296

5.  Cell models for McArdle disease and aminoglycoside-induced read-through of a premature termination codon.

Authors:  Kathryn E Birch; Ros M Quinlivan; Glenn E Morris
Journal:  Neuromuscul Disord       Date:  2012-07-20       Impact factor: 4.296

6.  Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry.

Authors:  Alejandro Lucia; Jonatan R Ruiz; Alfredo Santalla; Gisela Nogales-Gadea; Juan C Rubio; Inés García-Consuegra; Ana Cabello; Margarita Pérez; Susana Teijeira; Irene Vieitez; Carmen Navarro; Joaquín Arenas; Miguel A Martin; Antoni L Andreu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-01-16       Impact factor: 10.154

7.  Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity.

Authors:  S T Andersen; J Vissing
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-12       Impact factor: 10.154

8.  Permanent muscle weakness in McArdle disease.

Authors:  Aleksandra A Nadaj-Pakleza; Carlo M Vincitorio; Pascal Laforêt; Bruno Eymard; Elisabeth Dion; Susana Teijeira; Irene Vietez; Marc Jeanpierre; Carmen Navarro; Tanya Stojkovic
Journal:  Muscle Nerve       Date:  2009-09       Impact factor: 3.217

9.  Favorable responses to acute and chronic exercise in McArdle patients.

Authors:  José L Maté-Muñoz; Maria Moran; Margarita Pérez; Carolina Chamorro-Viña; Félix Gómez-Gallego; Catalina Santiago; Luis Chicharro; Carl Foster; Gisela Nogales-Gadea; Juan C Rubio; Antoni L Andreu; Miguel A Martín; Joaquín Arenas; Alejandro Lucia
Journal:  Clin J Sport Med       Date:  2007-07       Impact factor: 3.638

10.  Sodium valproate increases the brain isoform of glycogen phosphorylase: looking for a compensation mechanism in McArdle disease using a mouse primary skeletal-muscle culture in vitro.

Authors:  Noemí de Luna; Astrid Brull; Josep Maria Guiu; Alejandro Lucia; Miguel Angel Martin; Joaquin Arenas; Ramon Martí; Antoni L Andreu; Tomàs Pinós
Journal:  Dis Model Mech       Date:  2015-03-11       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.